BeiGene (BSP:B1GN34) COGS-to-Revenue : 0.17 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is BeiGene COGS-to-Revenue?

BeiGene's Cost of Goods Sold for the three months ended in Mar. 2024 was R$622 Mil. Its Revenue for the three months ended in Mar. 2024 was R$3,743 Mil.

BeiGene's COGS to Revenue for the three months ended in Mar. 2024 was 0.17.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. BeiGene's Gross Margin % for the three months ended in Mar. 2024 was 83.38%.

BeiGene COGS-to-Revenue Historical Data

The historical data trend for BeiGene's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene COGS-to-Revenue Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.17

0.23

0.14

0.20

0.15

BeiGene Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.18	0.16	0.12	0.17	0.17

BeiGene COGS-to-Revenue Calculation

BeiGene's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1861.532	/	12047.525
	=	0.15

BeiGene's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	622.152	/	3743.077
	=	0.17

BeiGene (BSP:B1GN34) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

BeiGene's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	622.152 / 3743.077
	=	83.38 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

BeiGene COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of BeiGene's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (BSP:B1GN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (BSP:B1GN34) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (BSP:B1GN34) Headlines

No Headlines